Candel Therapeutics, Inc.

NASDAQ:CADL

Biotechnology

Healthcare
$5.40 +0.56%

+$0.05 today

Market cap
$423.61M
Beta
-0.48
P/E (TTM)
-9.2
EPS (TTM)
-$0.87
52W Low $4.35High $9.57

Volume 1.79M

Average 1.82M

Returns on capital

Candel Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-73.5%

avg -53.2%

ROIC

-41.4%

avg -46.6%

ROA

-30.5%

avg -43.3%

Analysis

ROA is currently the strongest return metric at -30.5% versus its period average of -43.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Paul-Peter Tak FOCIS

President, Chief Executive Officer & DirectorUSD 1.03M66——

Seshu Tyagarajan

Chief Technical & Development OfficerUSD 613.23K5876.86K0.14%

Francesca Barone

Chief Scientific OfficerUSD 497.31K4877.36K0.14%

Charles Schoch

Senior VP, CFO, Treasurer & SecretaryUSD 412.03K41232.00K0.42%

Mark Sims

Chief Commercial Officer————

Theodore Jenkins

Vice President of Investor Relations & Business Development————

William Nichols Garrett

Chief Medical Officer—57136.50K0.25%

Ileen Winick

Chief People Officer————

Susan Stewart

Chief Regulatory Officer—65——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 17, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

1

$3.00M

Sells

5

$3.55M

Net Transaction Value

−$550,707.38

Net selling

Most Active

Tak Paul Peter

2 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 11, 26

Tak Paul Peter

Direct

Sell$620.9K
Sep 10, 26

Tak Paul Peter

Direct

Sell$2.5M
Aug 17, 26

Tyagarajan Seshu

Direct

Sell$84K
Jun 29, 26

Barone Francesca

Direct

Sell$235.8K
Jun 29, 26

Tyagarajan Seshu

Direct

Sell$70.2K
Feb 23, 26

Manning Paul B

Indirect

Buy$3M

Summary

Insiders reported 1 buys worth $3.00M and 5 sells worth $3.55M over the last 12 months. That adds up to net selling of $550,707.38. Tak Paul Peter was the most active insider with 2 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/AN/A
N/A6 analysts
Net IncomeN/AN/AN/A
N/A6 analysts
EBITN/AN/AN/A
N/A6 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Candel Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about CADL's management, answered from reported figures.

Who manages CADL?

Candel Therapeutics, Inc. (CADL) lists 9 active executives. The top listed executive is Mark Sims, Chief Commercial Officer.

Are CADL insiders buying or selling?

Recent insider activity shows net buying of $23.28M.